Valeant Pharmaceuticals Intl Inc VRX shares are trading higher by 22 cents (1.7 percent) at $11.28 in Friday's session.
After Thursday's close, the company announced FDA approval of VYZULTA, for the treatment of open angle glaucoma.
After a higher open, Valeant continued to rally but found resistance just ahead of Thursday's high ($11.79), reaching $11.67 and reversed course. It has continued to drift lower and make new lows for the session.
It has yet to reach Thursday's closing price of $11.06 as $11.10 stands as low for the session as of 11:10 a.m. EST.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.